Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285570 · ClinicalTrials.gov registry record · Phase 3
Ulimorelin Study of Efficacy and Safety (ULISES 007)
A Phase 3 study of Gastrointestinal Dysmotility, sponsored by Tranzyme.
- Completed
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
- 20
- Study locations
NCT01285570: Completed Phase 3 study of Gastrointestinal Dysmotility, sponsored by Tranzyme.
NCT01285570 is a Phase 3 study of Gastrointestinal Dysmotility that has completed, run by Tranzyme. The registered enrollment target is 332 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01285570, a Phase 3 study of Gastrointestinal Dysmotility, has completed, sponsored by Tranzyme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
- 20
- Study locations
Study Summary
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
Conditions Studied
Interventions
- DRUG Ulimorelin Intravenously (IV)
- DRUG 5% dextrose in water
Study Locations (20)
California
- Fountain Valley Regional Hospital - Fountain Valley
- Orange Coast Memorial Med. Ctr. - Fountain Valley
- USC, Colorectal Surgery Division - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
Florida
- Nature Coast Clinical Research - Inverness
- Jacksonville Center for Clinical Research - Jacksonville
- Pensacola Research Consultants - Pensacola
- Sunrise Clinical Research, Inc. - Sunrise
Oregon
- Bend Memorial Clinic - Bend
- Mt. Talbert Medical Offices - Clackamas
Colorado
- Denver VA Medical Center - Denver
Georgia
- ARS Clinical Trials - Powder Springs
Illinois
- So. Illinois Univ. School of Medicine - Springfield
Kentucky
- Univ. of Louisville, Dept. of Surgery - Louisville
Massachusetts
- UMass Memorial Medical Center - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
What the finished NCT01285570 record still lists
NCT01285570 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Gastrointestinal Dysmotility appearing as the primary indexed condition, and to 2 interventions - of which Ulimorelin Intravenously (IV) is the first listed.
NCT01285570 names 20 study sites across 13 states, led by California, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT01285570 about?
NCT01285570 is a clinical study titled "Ulimorelin Study of Efficacy and Safety (ULISES 007)". Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
What is the current status of trial NCT01285570?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2011-01. Estimated completion is 2012-01.
What conditions does trial NCT01285570 study?
This clinical trial studies the following conditions: Gastrointestinal Dysmotility.
What interventions are being tested in trial NCT01285570?
The interventions under investigation include: Ulimorelin Intravenously (IV) (DRUG), 5% dextrose in water (DRUG).
Who is sponsoring clinical trial NCT01285570?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01285570 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Dysmotility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01285570's enrollment target sits among peer trials
332 1061st of 2000 higher than 935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia